IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma

Conditions:   Squamous Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Metastatic Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharynx Squamous Cell Carcinoma;   Paranasal Sinus Squamous Cell Carcinoma;   Hypopharynx Squamous Cell Carcinoma;   Larynx Squamous Cell Carcinoma
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: IRX-2 Regimen
Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting

http://ift.tt/2BhbXbV